Rapport Therapeutics, Inc. (RAPP)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into Phase III development.
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 20 | $626 | $526.1 | -$99.9 | -15.96% |
 Marc Larkins Johnson & Johnson | 1.78M | $41.51M | $46.42M | $4.91M | 11.82% |
| NA Nizar Araji National Bank Of Canada /FI/ | 7 | $291.69 | $184.13 | -$107.56 | -36.87% |
| BG Bart Gancher Intech Investment Management LLC | 8,371 | $269,113.02 | $221,505.87 | -$47,607.15 | -17.69% |
 John H. Burbank III Passport Capital LLC | 1.55M | $35.87M | $40.47M | $4.61M | 12.84% |
Rapport Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Joon Lee Truist Securities | 187.24 | $5,536.55 | $4,909.31 | -$627.24 | -11.33% |
Rapport Therapeutics, Inc. (RAPP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rapport Therapeutics, Inc. ever had a stock split?
Rapport Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Abraham N. Ceesay CEO | NASDAQ (NMS) Exchange | 75383L102 CUSIP |
| US Country | 84 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Rapport Therapeutics, Inc. is a progressive clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule medicines aimed at treating patients with central nervous system (CNS) disorders. Established in 2022 and based in Boston, Massachusetts, the company leverages its expertise in neuroscience to target a range of debilitating conditions, focusing on creating therapies that address significant unmet medical needs.
Products and Services
- RAP-219
This is Rapport Therapeutics' leading product candidate, representing a pioneering approach in the treatment of focal epilepsy and other CNS disorders such as peripheral neuropathic pain and bipolar disorder. RAP-219 is an investigational small molecule crafted to inhibit TARPy8-containing AMPARs with remarkable picomolar affinity. The therapeutic aim of RAP-219 demonstrates Rapport Therapeutics' focused commitment to pushing the boundaries of CNS disorder treatment.
- RAP-199
A successor to RAP-219, RAP-199 stands out due to its targeted approach towards TARPy8 and distinctive chemical and pharmacokinetic properties. This compound underlines the company's ongoing efforts in expanding its portfolio with innovative molecules designed to target CNS disorders with high precision.
- Nicotinic Acetylcholine Receptor (nAChR) Programs
Rapport Therapeutics also advances its mission through the development of specific nicotinic acetylcholine receptor programs, notably:
- a6 nAChR: Targeted to treat chronic pain, this program aims to explore the therapeutic potential of nAChR subtypes in managing pain without the drawbacks of traditional pain management therapies.
- a9a10 nAChR: Geared towards the treatment of hearing disorders, this innovative approach reflects the company's dedication to addressing less common but equally challenging CNS disorders through targeted receptor modulation.
Contact Information
